In the ATT-MYC mouse model of liver cancer, transcriptional regulation of the Warburg effects and correlation between 18F-fluorodeoxyglucose glucose uptake by liver cancer
Keywords:
18-FFluorodeoxyglucose (FDG), MicroPET, Exon array expression, Hepatocellular carcinoma (HCC), Att-myc transgenic mice, Diethylnitrosamine (DEN), Butylated hydroxytoluene (BHT), Glucose metabolismAbstract
Background
It was previously reported that diethylnitrosamine (DEN) enhanced liver cancer progression in ATT-MYC mouse model of liver cancer. Radiogenomics is a new tool in advanced science technology that gives information on tumor biology, non-tumor surrounding tissue, the degree of tumor size and presence of necrosis of cells especially with joined micro computed tomography – positron emission tomographys (CT/PETs).
Aim
To evaluate the correlation of gene expression and non-invasive microPET information of the liver tumors at different points of the stage of growth.
Methods
Exon array expression of the liver of ATT-MYC mice treated with DEN or butylated hydroxytoluene (BHT) compared to control non-transgenic mice were analyzed by array track and the current data were also compared to microarray expression of liver tumor of ATT-MYC mice.
Results
The expression of genes responsible for glucose transport such as glut1, 3, 4, hk1, slc1a5, slc1a1, slc1a4, slc1a2, gp6c and gpc-1-3-4 were up-regulated significantly in DEN-treated transgenic mice immediately after end of treatment (p≤0.05), while glut2 (fold change 0.9503, p-value 0.4385) and hk2 (fold change 3.0589, p-value 0.0565) genes were increased not significantly immediately after end of treatment. Additionally, at 4.5-months of observation after the end of treatment slc1a5, slc38a2, glut1, glut4 and gpc3-4 genes had a significant fold change in liver tumor tissue in DEN treated mice when compared to BHT or control transgenic or non-transgenic one. While hk1, 2, slc5a1, slc1a4, glut2, glut3, g6pc and gpc-1 genes were increased non-significantly in the liver of treated mice when compared to control group at 4.5-months of observation after the end of treatment. Notably, c-myc, hif-1 and aldoa glycolytic genes were expressed significantly both time points of 4 and 8.5-months while ldhb, hk-2 and PKM2 were increased non-significantly in DEN treatment when compared to BHT/control non-transgenic animals.
Conclusion
There is a definitive correlation between genes responsible for glucose transport and 18F-Fluorodeoxyglucose (FDG) uptake in the early and advanced degree of liver carcinogenesis. This study of glucose pathway in Hepatocellular carcinoma (HCC) at different stages of early and advanced one is the potential for therapeutic anticancer therapy.
References
Pinheiro PS, Callahan KE, Jones PD, Morris C, Ransdell JM, Kwon D, et al. Liver cancer: A leading cause of cancer death in the United States and the role of the 1945-1965 birth cohort by ethnicity. JHEP Rep. 2019; 1(3): 162-169. doi: 10.1016/j. jhepr.2019.05.008
Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016; 122(22): 3430-3446. doi: 10.1002/cncr.30237
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of in-cidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. doi: 10.3322/caac.21492
Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018; 22(3): 141-150. doi: 10.5114/wo.2018.78941
Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol. Elalfy M et al 2013; 2(4): 43. doi: 10.3978/j.issn.2304-3865.2013.11.07
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and devel-oping world. World J Gastroenterol. 2017; 23(29): 5282-5294. doi: 10.3748/wjg.v23.i29.5282
Hueper K, Elalfy M, Laenger F, Halter R, Rodt T, Galanski M, et al. PET/CT imaging of c-Myc transgenic mice identifies the genotoxic N-nitroso-diethylamine as carcinogen in a short-term cancer bioassay. PLoS One. 2012; 7(2): e30432. doi: 10.1371/jour-nal.pone.0030432
Bai HX, Lee AM, Yang L, Zhang P, Davatzikos C, Maris JM, et al. Imaging genomics in cancer research: Limitations and promises. Br J Radiol. 2016; 89(1061): 20151030. doi: 10.1259/ bjr.20151030
Li Y-C, Yang C-S, Zhou W-L, Li H-S, Han Y-J, Wang Q-S, et al. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol. 2018; 24(4): 494-503. doi:
3748/wjg.v24.i4.494 10. von Falck C, Rodt T, Halter R, Spanel R, Galanski M, Borlak J. Combined microPET/CT for imaging of hepatocellular carci-noma in mice. Front Biosci (Landmark Ed). 2009; 14: 2193-2202. doi: 10.2741/3371
Bibby M. Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur J Cancer. 2004; 40(6): 852-857. doi: 10.1016/j.ejca.2003.11.021
Calvisi DF, Thorgeirsson SS. Molecular mechanisms of hepa-tocarcinogenesis in transgenic mouse models of liver cancer. Toxi-col Pathol. 2005; 33(1): 181-184. doi: 10.1080/01926230590522095
Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, So-dir NM, et al. Modelling Myc inhibition as a cancer therapy. Na-ture. 2008; 455(7213): 679-683. doi: 10.1038/nature07260
Dalemans W, Perraud F, Le Meur M, Gerlinger P, Courthey M, Pavirani A. Heterologous protein expression by transimmor-talized differentiated liver cell lines derived from transgenic mice (hepatomas/α1 antitrypsin/ONC mouse). Biologicals. 1990; 18(3): 191-198. doi: 10.1016/1045-1056(90)90006-l
Ssniff Spezialdiaten. ssniff Web site. http://www.ssniff.de/. Accessed January 16, 2020.
Hueper K, Elalfy M, Länger F, Halter R, Rodt T, Vaske B, et al. MikroCT und mikroPET zur beurteilung und quantifizierung der leberzellkarzinom-entstehung im rahmen einer toxikologisch-en untersuchung im transgenen mausmodell [In: German]. RöFo - Fortschritte auf dem Gebiet der R. 2010; 182(11). doi: 10.1055/s-0030-1268295
Hueper K, Elalfy M, Länger F, Halter R, Rodt T, Hartung D, et al., editors. Einsatz der in vivo μCT und 18F-FDG-μPET Bildgebung zur frühzeitigen Identifizierung von Karzinogenen in einem transgenen Mausmodell der Leberzellkarzinomentste-hung. RöFo - Fortschritte auf dem Gebiet der R. 2011; 183(S 01): doi: 10.1055/s-0031-1279558
Weber SM, Peterson KA, Durkee B, Qi C, Longino M, War-ner T, et al. Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: Accuracy is dependent on adequate contrast enhancement. J Surg Res. 2004; 119(1): 41-45. doi: 10.1016/S0022-4804(03)00357-3
Londhe KB, Borlak J. A cross-platform comparison of ge-nome-wide expression changes of laser microdissected lung tis-sue of C-Raf transgenic mice using 3’ IVT and exon array. PLoS One. 2012; 7(7): e40778. doi: 10.1371/journal.pone.0040778
Liu Y-C, Li F, Handler J, Huang CRL, Xiang Y, Neretti N, et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One. 2008;3(7): e2722. doi: 10.1371/journal.pone.0002722
Lee J-S, Chu I-S, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12): 1306-1311. doi: 10.1038/ng1481
Mahmoud EM. Limitation of Liver tumor promoting proper-ties of butylated hydroxytoluene in non-transgenic C57BL6 black mouse. 2016; 6(1): 1-6.
Long NM, Smith CS. Causes and imaging features of false positives and false negatives on 18 F-PET/CT in oncologic im-aging. Insights Imaging. 2011; 2(6): 679-698. doi: 10.1007/s13244- 010-0062-3
Zhao J, Zhang Z, Nie D, Ma H, Yuan G, Su S, et al. PET Imaging of Hepatocellular Carcinomas: 18F-Fluoropropion-ic Acid as a Complementary Radiotracer for 18F-Fluorode-oxyglucose. Mol Imaging. 2019; 18: 1536012118821032. doi: 10.1177/1536012118821032
Cavalcante IP, Zerbini MCN, Alencar GA, Mariani BdP, Buchpiguel CA, Almeida MQ, et al. High 18F-FDG up-take in PMAH correlated with normal expression of Glut1, HK1, HK2, and HK3. Acta Radiol. 2016; 57(3): 370-377. doi: 10.1177/0284185115575195
Hong R, Lim S-C. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocar-cinoma. World J Gastroenterol. 2012; 18(2): 168-174. doi: 10.3748/ wjg.v18.i2.168
Xu H-L, Li M, Zhang R-J, Jiang H-J, Zhang M-Y, Li X, et al. Prediction of tumor biological characteristics in different Submit your article to this journal | https://openventio.org/submit-manuscript/ colorectal cancer liver metastasis animal models using 18F-FDG and 18F-FLT. Hepatobiliary Pancreat Dis Int. 2018; 17(2): 140-148. doi: 10.1016/j.hbpd.2018.03.006
Rahmim A, Bak-Fredslund KP, Ashrafinia S, Lu L, Schmidtle-in CR, Subramaniam RM, et al. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET ra-diomic features. Eur J Radiol. 2019; 113: 101-109. doi: 10.1016/j. ejrad.2019.02.006
Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, et al. Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res. 2013; 33(10): 4219-4228.
Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clinical Oncol. 2010; 28(23): 3746-3753. doi: 10.1200/ JCO.2009.27.4662
Kaida H, Azuma K, Kawahara A, Yasunaga M, Kitasato Y, Hattori S, et al. The correlation between FDG uptake and biologi-cal molecular markers in pancreatic cancer patients. Eur J Radiol. 2016; 85(10): 1804-1810. doi: 10.1016/j.ejrad.2016.08.007
Bolton RCD, Calapaquí-Terán AK, Giammarile F, Rubello D. Role of 18F-FDG-PET/CT in establishing new clinical and ther-apeutic modalities in lung cancer. Rev Esp Med Nucl Imagen Mol. 2019; 38(4): 229-233. doi: 10.1016/j.remn.2019.02.003
Shim J-R, Lee SD, Han S-S, Lee SJ, Lee DE, Kim S-K, et al. Prognostic significance of 18F-FDG PET/CT in patients with colorectal cancer liver metastases after hepatectomy. Eur J Surg Oncol. 2018; 44(5): 670-676. doi: 10.1016/j.ejso.2018.01.243
Fadaka A, Ajiboye B, Ojo O, Adewale O, Olayide I, Emuow-hochere R. Biology of glucose metabolization in cancer cells. J Oncol Sci. 2017; 3(2): 45-51. doi: 10.1016/j.jons.2017.06.002
Lee NC, Carella MA, Papa S, Bubici C. High expression of glycolytic genes in cirrhosis correlates with the risk of develop-ing liver cancer. Front Cell Dev Biol. 2018; 6: 138. doi: 10.3389/ fcell.2018.00138
Sawayama H, Ishimoto T, Sugihara H, Miyanari N, Miyamoto Y, Baba Y, et al. Clinical impact of the Warburg effect in gastroin-testinal cancer. Int J Oncol. 2014; 45(4): 1345-1354. doi: 10.3892/ ijo.2014.2563
Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepato-cellular carcinoma. Biomed Pharmacother. 2019; 119: 109402. doi: 10.1016/j.biopha.2019.109402
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.